Raymond James & Associates Myriad Genetics Inc Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
A detailed history of Raymond James & Associates transactions in Myriad Genetics Inc stock. As of the latest transaction made, Raymond James & Associates holds 55,204 shares of MYGN stock, worth $223,576. This represents 0.0% of its overall portfolio holdings.
Number of Shares
55,204Holding current value
$223,576% of portfolio
0.0%Shares
14 transactions
Others Institutions Holding MYGN
# of Institutions
237Shares Held
96MCall Options Held
95.4KPut Options Held
18.2K-
Black Rock Inc. New York, NY15.2MShares$61.4 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.7MShares$43.2 Million0.0% of portfolio
-
State Street Corp Boston, MA5.27MShares$21.3 Million0.0% of portfolio
-
Disciplined Growth Investors Inc Minneapolis, MN4.73MShares$19.2 Million0.98% of portfolio
-
Wellington Management Group LLP Boston, MA4.59MShares$18.6 Million0.01% of portfolio
About MYRIAD GENETICS INC
- Ticker MYGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 80,634,800
- Market Cap $327M
- Description
- Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...